Aclaris says Biosion-licensed bosakitug missed its phase 2 eczema endpoint
Aclaris (NASDAQ: ACRS) said on November 16, 2026 that bosakitug, licensed from Biosion outside Greater China, missed the week-24 EASI endpoint in NCT07011706. China phase 3 studies at Chia Tai Tianqing are separate.
Aclaris Therapeutics (NASDAQ: ACRS) said on November 16, 2026 that bosakitug (ATI-045), the anti-TSLP antibody it licensed from Biosion, missed the primary and secondary endpoints of a phase 2 trial in moderate-to-severe atopic dermatitis. The primary endpoint, recorded as NCT07011706, was the percent change from baseline in the Eczema Area and Severity Index at week 24. Aclaris published no response rates and no placebo difference. The result applies to Aclaris’s territory, which excludes mainland China, Hong Kong, Macau and Taiwan. Chia Tai Tianqing’s Greater China phase 3 trials of the same antibody, coded TQC2731, remain listed separately in severe asthma and chronic rhinosinusitis with nasal polyps.
Biosion, Inc., named in the license as a Nanjing company, granted the rights on November 18, 2024. The Form 8-K covers bosakitug (BSI-045B) and a TSLP/IL-4R bispecific, BSI-502 (now ATI-052). In aggregate, Aclaris agreed to pay $30.0 million upfront, $4.5 million to reimburse development costs, and $6.2 million for further development costs and drug product; to issue warrants for 14,281,985 shares; to pay up to $125 million on regulatory milestones that start at product approval and up to $795 million on sales milestones; and to pay a tiered low-to-mid-single-digit royalty plus a share of sublicense income. Aclaris may terminate the license for convenience. A collaboration agreement with Biosion and Chia Tai Tianqing, the Greater China licensee, sends a portion of that consideration directly to Chia Tai Tianqing. In its 2024 annual report, Aclaris said the fair value of the consideration, $85.6 million, was expensed as in-process research and development because the assets had no alternative future use. The unpaid milestones stay contingent. The 8-K summary does not split them by indication, so this atopic-dermatitis miss does not by itself show that every regulatory milestone is unreachable.
The November 16 8-K repeats the press release: the trial missed its primary and secondary endpoints; pharmacodynamic tests showed what the company called robust TSLP target engagement and downregulation of Th1, Th2 and Th17 markers; bosakitug was generally well tolerated. No EASI change, no responder rate and no adverse-event count is in that filing.
NCT07011706 (ATI-045-AD-201) is a randomized, double-blind, placebo-controlled study. Actual enrollment is 110. Participants were adults 18 to 70 with chronic moderate-to-severe atopic dermatitis, an EASI score of at least 16, body surface area of at least 10%, and an inadequate response to topical treatment or a medical reason not to use topicals. Secondary endpoints listed on the record, which the company says were also missed, include validated Investigator Global Assessment success, EASI-50, EASI-75 and EASI-90, pruritus scores, and body-surface-area change, all at week 24. The dose is not in the registry or the November 16 release. Primary completion is recorded as September 21, 2026. Estimated study completion is November 24, 2026. The record was last updated on September 29, 2026, and on November 18 it still had no results posted. Sites are in the United States and Canada.
When Aclaris signed the license, its November 18, 2024 release cited a completed single-arm U.S. study in 22 patients as showing a pharmacodynamic, safety and efficacy profile that “could position it as a potential best-in-class therapy.” The 2026 trial is the placebo-controlled test of that description. Chief executive Neal Walker said the result did not overcome what he called the historical difficulty of treating atopic dermatitis with an anti-TSLP antibody alone, and that development priorities are unchanged: the oral ITK/JAK3 inhibitor modzatinib, now in a phase 2b trial in lichen planus; an IND for the oral ITK inhibitor ATI-9494 expected this quarter; and a phase 2b trial of ATI-052 in eosinophilic esophagitis intended for the first quarter of 2027. Bosakitug is not on that list.
The Greater China program is a different sponsor, a different territory and different diseases. NCT06829784 (TQC2731-III-01) is a phase 3 in poorly controlled severe asthma, sponsored by Chia Tai Tianqing, listed as recruiting, with estimated enrollment of 660 and a primary endpoint of annualized asthma exacerbations. The record was updated on August 19, 2026, and primary completion is estimated for December 2027. NCT07107256 is a phase 3 in chronic rhinosinusitis with nasal polyps, listed as active, not recruiting, with actual enrollment of 246 and primary completion estimated for March 2027. Neither record is an atopic-dermatitis study, and the November 16 release does not say those trials will stop.
Other China-origin TSLP antibodies are already on a different rights map, including Hengrui-origin SHR-1905 (AIO-001), noted in this desk’s Windward Bio account. They are not the asset that missed NCT07011706.
The next records are a results posting for NCT07011706 that shows the week-24 EASI difference, any Aclaris filing that says bosakitug will be stopped, partnered or continued, and the Chia Tai Tianqing phase 3 readouts, which this eczema result does not replace.
Checked November 18, 2026 against Aclaris’s November 16, 2026 press release and Form 8-K, the November 18, 2024 license Form 8-K and 2024 annual-report note, and ClinicalTrials.gov records NCT07011706, NCT06829784 and NCT07107256.